JorgeGermanDarcourtMD

Oncology • Sugar Land, TX

Breast Cancer, Hematologic Oncology

Physician

Join to view full profile

Dr. Darcourt is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Darcourt's full profile

Already have an account?

Office
1350 First Colony Blvd
Sugar Land, TX 77479
Phone+1 281-277-5200

Fax+1 281-276-5201

Education & Training

Baylor College of MedicineFellowship, Hematology and Medical Oncology, 2006 - 2009
University of Texas Health Science Center at HoustonResidency, Internal Medicine, 2003 - 2006
University of Buenos AiresClass of 2000

Certifications & Licensure

TX State Medical License 2006 - 2025
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Chloroquine With Taxane Chemotherapy for Advanced or Metastatic Breast Cancer After Anthracycline Failure (CAT) Start of enrollment: 2011 Sep 01
Completed
Phase 2
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 2
PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer Start of enrollment: 2012 Jul 01
Withdrawn
Phase 2
Olive Oil for High Risk Breast Cancer Prevention in Women Start of enrollment: 2013 Dec 01
Completed
Phase 2, Phase 3
Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel Start of enrollment: 2014 Feb 01
Completed
Phase 2
T-DM1 With Abraxane and Lapatinib for Metastatic HER2 Positive Breast Cancer Start of enrollment: 2013 Oct 01
Completed
Phase 1
TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Start of enrollment: 2017 Apr 24
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
Prognostic impact of biologically equivalent dose in stereotactic body radiotherapy for renal cancer.
Kevin T Tran, Neil C Chevli, Jay A Messer, Waqar Haque, Andrew M Farach
Clinical and Translational Radiation Oncology. 2023-03-01
11 citations
A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Kai Sun, Yitian Xu, Licheng Zhang, Polly Niravath, Jorge Darcourt
Clinical Cancer Research. 2022-10-14
53 citations
A phase 1/2 clinical trial of the nitric oxide synthase inhibitor L-NMMA and taxane for treating chemoresistant triple-negative breast cancer.
Andrew W Chung, Kartik Anand, Ann C Anselme, Alfred A Chan, Nakul Gupta
Science Translational Medicine. 2021-12-15

Press Mentions

Report Shows Drop in Cancer Deaths, but Troubling Data for Women and Younger AdultsJanuary 16th, 2025
Managing Cancer Care During COVID-19: 4 Oncologists Weigh InJuly 22nd, 2020
New Technology Reduces Chemotherapy-Related Hair Loss for Patients at Houston Methodist SL HospitalJanuary 31st, 2019
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member